<DOC>
	<DOCNO>NCT00727597</DOCNO>
	<brief_summary>The hope study gather data information tolerability effectiveness Lexiva versus Sustiva patient generally underrepresented clinical trial .</brief_summary>
	<brief_title>A Study Underrepresented Patient Population Regimen Tolerability : SUPPoRT</brief_title>
	<detailed_description>The objective study gain tolerability efficacy data Norvir-boosted Lexiva versus Sustiva , use combination Epzicom , components first-line , daily regimen treatment HIV-1 infection patient population underrepresented US clinical research .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Screening plasma HIV1 RNA viral load &gt; 5000 copies/mL Selfidentification nonWhite/Caucasian European geographic ancestry ( i.e. , individual eligible she/he White/Caucasian European ancestry ; OR individual eligible she/he indicate mix White/Caucasian European ancestry AND one geographic ancestry ) ; Antiretroviralnaïve ( treatment antiretroviral drug 28 day prior study entry ≤14 day treatment ever antiretroviral drug ) Negative test HLAB*5701 allele Ability willingness give write informed consent Either gender eligible , enrollment least two female subject every one male subject strongly encourage . A female subject eligible participate study : 1 . Nonchildbearing potential , 2 . Childbearing potential negative pregnancy test screen agree use one follow method contraception : . Agreement complete abstinence intercourse 2 week prior administration investigational product , throughout study , 2 week discontinuation study medication ; ii . Double barrier contraception ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) ; iii . Any intrauterine device ( IUD ) publish data show expected failure rate le 1 % per year ( IUDs meet criterion ) ; iv . Any method publish data show low expected failure rate method le 1 % per year . v. Sterilization ( female subject male partner female subject ) Screening HIV1 genotype indicate presence follow mutation reverse transcriptase ( RT ) region : K65R , L74V , K103N , Y115F , Y181C/I , Y188C/L/H G190S/A , combination two thymidine analog mutation ( M41L , D67N , K70R , K219Q E ) include change either L210 T215 , associate resistance abacavir , lamivudine , efavirenz ; OR within protease region , detection follow mutation associate resistance fosamprenavir ritonavir : I50V , I54L/M , I84V , combination two mutation V32I+I147V Positive Hepatitis B surface antigen ( HBsAg+ ) Requirement active treatment hepatitis C virus infection , indicate positive Hepatitis C Virus serology AND either : 1 . Decompensated liver disease , 2 . Aspartate aminotransferase ( AST ) &gt; 3X upper limit normal ( ULN ) , 3 . Alanine aminotransferase ( ALT ) &gt; 3X ULN Currently pregnant , intend become pregnant study period , breastfeed Use immunomodulators ( e.g. , interleukin , interferon , cyclosporine ) , vaccination , systemic cytotoxic chemotherapy , investigational therapy within 28 day prior study entry . Chronic treatment prednisone daily dose 10 mg less permit . Acute treatment ( le 21 day ) large dos corticosteroid acute therapy permit . Active suspected drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement Judged investigator significant risk fail comply provision protocol cause harm self seriously interfere validity study result Active acute Centers Disease Control Clinical Category C event screening . ( Note : Treatment acute event must complete least 28 day prior screen . ) Clinically relevant pancreatitis clinically relevant hepatitis screen Hgb &lt; 8g/dl , platelet count &lt; 50,000/mm3 , calculate creatinine clearance &lt; 50ml/min via CockroftGault equation , AST ALT &gt; 5X ULN Any Grade 4 laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>